title: [Spread of surgical indication for hepatoma with postoperative transcatheter arterial infusion].
abstract: We evaluated the reduction surgery and the postoperative TAI for unresectable hepato-cellular carcinoma (HCC). Eight patients underwent reduction surgery and postoperative TAI (group I). Twenty-five patients underwent combination therapy with TAI, TAE, EI, hyperthermia and irradiation, who had not undergone reduction surgery (group II). Nine patients underwent a relative noncurative operation (group III). We studied the prognosis of these three groups.
  
  
  RESULTS
  The one-year survival rates were 85.7% in group I, 38.6% in group II and 55.5% in group III. The three-year survival rates were 42.9% in group I, 10.7% in group II and 55.5% in group III. There was a significant difference of prognosis between group I and group II (p less than 0.05, generalized Wilcoxon). These results suggest that reduction surgery and post operative TAI for unresectable HCC improve the prognosis.
authors.affiliation: Second Dept. of Surgery, School of Medicine, Kanazawa University.
authors.forename: M
authors.initials: M
authors.lastname: Kiriyama
authors.forename: R
authors.initials: R
authors.lastname: Izumi
authors.forename: M
authors.initials: M
authors.lastname: Urade
authors.forename: S
authors.initials: S
authors.lastname: Tani
authors.forename: K
authors.initials: K
authors.lastname: Kitabayashi
authors.forename: H
authors.initials: H
authors.lastname: Tomita
authors.forename: H
authors.initials: H
authors.lastname: Horichi
authors.forename: K
authors.initials: K
authors.lastname: Shimizu
authors.forename: I
authors.initials: I
authors.lastname: Miyazaki
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D003131:Combined Modality Therapy; D006801:Humans; D006979:Hyperthermia, Induced; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D011182:Postoperative Care; D011379:Prognosis; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents